BAYPAN study: a double-blind phase III randomized trial comparing gemcitabine plus sorafenib and gemcitabine plus placebo in patients with advanced pancreatic cancer

New Guidelines to Evaluate the Response to Treatment in Solid Tumors

Patrick Therasse, Susan G. Arbuck, Elizabeth A. Eisenhauer et al. · JNCI Journal of the National Cancer Institute · 2000 · 15.7K citations

Medicine, Oncology, Cancer Pharmacology +12

FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer

Thierry Conroy, Françoise Desseigne, Marc Ychou et al. · New England Journal of Medicine · 2011 · 7.8K citations · Full text

Medicine, Oncology, Pharmacology +13

Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation

Paul B. Chapman, Axel Hauschild, Caroline Robert et al. · New England Journal of Medicine · 2011 · 7.7K citations · Full text

Medicine, Molecular Genetics, Oncology +9

Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.

Howard A. Burris, Malcolm J. Moore, John Sahl Andersen et al. · Journal of Clinical Oncology · 1997 · 5.9K citations

Medicine, Oncology, Pharmacotherapy +16

BAY 43-9006 Exhibits Broad Spectrum Oral Antitumor Activity and Targets the RAF/MEK/ERK Pathway and Receptor Tyrosine Kinases Involved in Tumor Progression and Angiogenesis

Scott M. Wilhelm, Christopher Carter, LiYa Tang et al. · Cancer Research · 2004 · 4K citations · Full text

Medicine, Oncology, Pharmacology +17